📊 ENGNW Key Takeaways
Is ENGNW a Good Investment? Thesis Analysis
enGene Holdings is a pre-revenue biotech company with significant cash burn, negative operating income of -$31.2M and negative free cash flow of -$29.1M, indicating it is not yet commercially viable. While the company maintains adequate liquidity with $36.6M in cash and a strong balance sheet with minimal debt, the burn rate suggests limited runway without additional capital raises or achieving clinical milestones.
Why Buy ENGNW? Key Strengths
- Strong balance sheet with $281.5M stockholders' equity and minimal debt (0.00x debt/equity ratio)
- Adequate liquidity position with $36.6M cash and 11.75x current ratio providing runway for operations
- Biological products sector with potential for high-value therapeutic development
ENGNW Investment Risks to Consider
- Pre-revenue stage with negative operating income of -$31.2M and negative free cash flow of -$29.1M indicating ongoing cash burn
- Lack of revenue generation suggests clinical programs have not yet achieved commercialization or FDA approval
- Annual cash burn of ~$29M against current cash balance suggests less than 2 years of runway without dilutive financing
- Negative ROE of -10.6% and ROA of -8.8% reflect value destruction for shareholders
Key Metrics to Watch
- Cash burn rate and runway to profitability or next inflection point
- Clinical trial progress and regulatory milestones for pipeline candidates
- Path to revenue generation and proof of commercial viability
ENGNW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 11.75x current ratio provides a solid financial cushion.
ENGNW Profitability Ratios
ENGNW vs Healthcare Sector
How enGene Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENGNW Overvalued or Undervalued?
Based on fundamental analysis, enGene Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENGNW Balance Sheet & Liquidity
ENGNW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: enGene Holdings Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $1.46 reflects profitable operations.
ENGNW Growth Metrics (YoY)
ENGNW Capital Allocation
ENGNW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for enGene Holdings Inc. (CIK: 0001980845)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENGNW
What is the AI rating for ENGNW?
enGene Holdings Inc. (ENGNW) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENGNW's key strengths?
Claude: Strong balance sheet with $281.5M stockholders' equity and minimal debt (0.00x debt/equity ratio). Adequate liquidity position with $36.6M cash and 11.75x current ratio providing runway for operations.
What are the risks of investing in ENGNW?
Claude: Pre-revenue stage with negative operating income of -$31.2M and negative free cash flow of -$29.1M indicating ongoing cash burn. Lack of revenue generation suggests clinical programs have not yet achieved commercialization or FDA approval.
What is ENGNW's revenue and growth?
enGene Holdings Inc. reported revenue of N/A.
Does ENGNW pay dividends?
enGene Holdings Inc. does not currently pay dividends.
Where can I find ENGNW SEC filings?
Official SEC filings for enGene Holdings Inc. (CIK: 0001980845) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENGNW's EPS?
enGene Holdings Inc. has a diluted EPS of $0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENGNW a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, enGene Holdings Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENGNW stock overvalued or undervalued?
Valuation metrics for ENGNW: ROE of -10.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENGNW stock in 2026?
Our dual AI analysis gives enGene Holdings Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENGNW's free cash flow?
enGene Holdings Inc.'s operating cash flow is $-28.9M, with capital expenditures of $153.0K.
How does ENGNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -10.6% (avg: 15%), current ratio 11.75 (avg: 2).